

Supplementary Figure 3. AIF loss provoked hematopoietic defaults in adult mice. (**a**) Kaplan- Meier survival probability of WT and *AIF* $^{-/Y}$ tamoxifen-treated mice. (**b**) Cellularity assessed in BM and thymus from WT and *AIF* $^{-/Y}$ mice (n = 8 animals per group). Representative images of a thymus from control and *AIF* $^{-/Y}$ mice are shown. (**c**) Left, percentages of CD4-/CD8- (DN), CD4+/CD8+ (DP), CD4+, and CD8+ thymocytes in WT and *AIF* $^{-/Y}$ tamoxifen-treated mice (n = 12 animals per group). *Right*, fre quencies of DN1-DN4 thymocytes from WT and *AIF* $^{-/Y}$ tamoxifen-treated animals (n = 12 mice per group). (**d**) ΔΨm assessment performed in BM cells from WT and *AIF* $^{-/Y}$ tamoxifen-treated mice (n = 12 animals per group). (**e**) Mitochondrial ROS levels recor ded in BM cells obtained from WT and *AIF* $^{-/Y}$ tamoxifen-treated animals (n = 9 mice per group). (**f**) ATP levels recorded in BM cells obtained from WT and *AIF* $^{-/Y}$ tamoxifen-treated animals (n = 6 mice per group). (**g**) The number of LT-HSC, ST-HSC, and MPP assessed in WT and *AIF* $^{-/Y}$ mice (n = 7 animals per group). **(h)** ΔΨm assessment performed in thymocytes from WT and *AIF* $^{-/Y}$ ta moxifen-treated mice (n = 9 animals per group). (**i**) Mitochondrial ROS levels recorded in thymocytes obtained from WT and *AIF* $^{-/Y}$ tamoxifen-treated animals (n = 9 mice per group). (**j**) ATP levels recorded in thymocytes obtained from WT and *AIF* $^{-/Y}$ tamoxifen-treated animals (n = 6 mice per group). Statistical significance was calculated by Mann Whitney test in samples obtained from mi ce 28 days after the first tamoxifen injection. Bars represent mean ± SEM. *Aifm1* $^{fl/Y}$*;Rosa26-CreERT2*- tamoxifen-injected mice were used as control (WT) animals.